{"id":"W2898400750","doi":"10.1093/annonc/mdy272.355","title":"LUCY: A phase IIIb, real-world study of olaparib in HER2-negative metastatic breast cancer patients with a BRCA mutation","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Olaparib; Metastatic breast cancer; Oncology; Internal medicine; BRCA mutation; Breast cancer; Taxane; Cohort; Progression-free survival; Eribulin; Cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003217493,0.001585354,0.001591102,0.0002942387,0.0005599048,0.001303482,0.001139688,0.001897347,0.007108689],"category_scores_gemma":[0.001592137,0.000583032,0.001411105,0.0004474436,0.001543535,0.001211287,0.0006332214,0.004045512,0.001994864],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001319928,"about_ca_system_score_gemma":0.002347716,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001089142,"about_ca_topic_score_gemma":0.002751995,"domain_scores_codex":[0.9991558,0.0004495984,0.00002650265,0.0001460695,0.0000883655,0.0001335858],"domain_scores_gemma":[0.9987375,0.0001828466,0.0003435025,0.0001007892,0.00009359587,0.0005417578],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.803956,0.05958603,0.009009493,0.002003561,0.001510417,0.0004328028,0.0003882797,0.002353717,0.01582316,0.0007800702,0.02159026,0.08256625],"study_design_scores_gemma":[0.8015903,0.1789808,0.008808907,0.00008768486,0.0003377805,0.0004355901,0.00005382478,0.0008464881,0.0009115857,0.0002952407,0.007612383,0.00003941734],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9619398,0.008262192,0.001426219,0.003621934,0.0003236962,0.01018571,0.007550138,0.0003479705,0.006342348],"genre_scores_gemma":[0.9590696,0.004177018,0.004588029,0.004872642,0.000458692,0.01070392,0.009328795,0.00009892107,0.006702315],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007108689,"threshold_uncertainty_score":0.02378094,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05783370770299373,"score_gpt":0.4382425195671686,"score_spread":0.3804088118641749,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}